Introduction
Status epilepticus (SE) is a neurological emergency, associated with significant morbidity and mortality, which requires early recognition and treatment. Treatment of SE has not changed in the last few decades. Currently, benzodiazepine (BZD) (lorazepam or diazepam) followed by phenytoin (PHT) is still considered the most effective treatment in the majority of the guidelines, 1,2 with an efficacy of 70%. 3 All these guidelines follow the Treiman
Veterans Study conducted in 1998 in which no differences were observed between treatment with lorazepam alone, diazepam plus PHT, and phenobarbital alone, whereas PHT alone was less effective. 4 Nowadays the use of benzodiazepines followed by valproate is also licensed in a few countries for this purpose 5 because some randomized case-control studies have found efficacy similar to phenytoin and valproate administered after benzodiazepines. 6 Once first-and second-line treatments have failed, SE is considered refractory (RSE); this occurs in 9-31% of patients with status epilepticus. 7 In refractory generalized tonic-clonic SE, aggressive treatment, including coma with anesthetic drugs, is usually necessary. 1,2 The use of other antiepileptic drugs (AED)
prior to the induction of pharmacological anesthesia should be considered in older patients, patients with comorbidities, and, particularly, patients with other types of SE. In this context intravenous (iv) levetiracetam (LEV) used as third-or greater line treatment has shown efficacy of 50-60% in several case series, 8 even though it seems roughly as effective as benzodiazepines when it is used as first-line treatment. 9 However, it appears possibly less effective compared to VPA or PHT in controlling SE after benzodiazepines. [11] [12] [13] [14] We report the effectiveness, safety and role of LCM in patients with SE treated with ivLCM when first-and second-line AEDs have failed. In contrast to other published series, LCM was always added as a third or subsequent drug (after benzodiazepines and at least one traditional AED). Generally accepted guidelines were followed at all times and no changes in the usual clinical practice were made.
Methods
We prospectively identified patients diagnosed with SE who received ivLCM at six Spanish Hospitals: Hospital Universitari de Bellvitge, Hospital Universitario La Fe, Hospital Vall d'Hebró n, Hospital General de Granollers, Hospital Povisa, and Hospital Virgen de las Nieves. All patients received at least one dose of ivLCM for treatment of SE between September 2010 and March 2012. All included patients were treated following a standard protocol (BZD plus PHT and/or VPA, and in many cases LEV), so LCM was always used as add-on therapy in the treatment of established SE refractory to usual agents or when were contraindicated.
Patient medical charts were carefully completed regarding electrophysiological data, seizure type, etiology, onset and duration of SE, order in which AEDs were administered, doses of ivLCM and concomitant AEDs, tolerability, and outcome. A standardized data sheet was used for documentation in all participating centers.
The following contraindications were considered in this standard protocol: BZDs were contraindicated in respiratory failure and Lennox-Gastaut syndrome; PHT was contraindicated in hepatic failure, allergy, disorders of heart rhythm and important unpredictable pharmacological interaction; and VPA was contraindicated in hepatic failure and thrombocytopenia.
Patients with whom the standard protocol was not followed were excluded. Anoxic myoclonic SE patients (because of the implicit poor prognosis) were excluded. SE was diagnosed according to the ILAE definition: (1) any seizure lasting for 30 min or longer or (2) intermittent seizures repeating within 30 min without full recuperation of consciousness. SEs were classified according to their semiology and with EEG support into generalized convulsive SE, focal motor SE (including epilepsia partialis continua, EPC) or non-convulsive SE. Cessation of SE was defined as disappearance of EEG status-seizure activity (all patients with the diagnosis of NCSE were monitored with continuous EEG monitoring) or disappearance of previous ictal symptoms without any suspicion of ongoing subclinical seizure activity, if confirmed by a subsequent EEG recording. We considered SE controlled if no change in antiepileptic medication was needed for at least 48 h after clinical or electrographic resolution. The last antiepileptic drug (AED) administered before SE cessation was defined as effective or termination drug. The study was approved by the local ethical committee. Consent procedures were established by local ethical committee regulation for patients who required emergency treatment.
Results
Thirty-four patients (52.9% men) aged between 22 and 86 years with refractory SE (RSE) were included in the study. SE was the initial presentation in 52.9% (18) patients, and in 58.9% (20) patients the etiology was symptomatic. In 82.4% (28) patients the SE was focal motor SE (FMSE), and in 14.7% (5) non-convulsive SE (NCSE); in only in 2.8% (1) was it generalized convulsive SE (GCSE). An ictal EEG previous to LCM treatment was carried out on all but two patients. Demographic data are presented in Table 1 .
The median interval from SE onset to the start of SE therapy was 0.3-240 h (median 4.5 h). All but five patients received benzodiazepines as first-line treatment. BZDs were contraindicated in a patient with Lennox-Gastaut syndrome and 4 patients with severe respiratory diseases. All received PHT or VPA as first-or second-line treatment (29 as second-line). PHT was contraindicated in 1 patient due to allergy, 6 due to important pharmacological interactions, 1 due to acute auricular fibrillation, and 2 due to auricular-ventricular block. VPA was contraindicated in 6 patients due to severe hepatopathy. All but 4 patients received LEV (contraindicated due to severe renal disease). LCM was used as a fourth or later option in 26 patients (76.5%). LCM was started after a median interval latency of 1.0-250 h (median 48.0 h). The first LCM bolus was 400 mg in 17 patients (50%), 300 in 9 (26.5%), 200 in 7 (20.6%), and 100 in 1 (2.9%). For 22 (64.7%) patients LCM terminated the SE, and in 17 of them, SE ceased within 12 h after the first administration of LCM (9 patients before 60 min after ivLCM loading dose). In 12 patients, further AED therapy or anesthesia was required. Oral or IV LCM as an adjunct AED, range 100-600 mg (mean 323.53 mg), was maintained in most of these patients. In 3 patients (8.8%) SE could not be terminated. SE termination was confirmed by EEG in all NCSE ( Table 2 ).
All adverse events were mild in intensity, and they were observed in only 2 patients (5.9%). One of these reported diplopia while the other patient presented confused state and nystagmus. In both patients the symptomatology was resolved by LCM dose reduction. There were no patients who required LCM discontinuation. Seven patients died (20.6%) during the month following due to acute illness (infection, stroke, etc.) or complications related to the SE.
Discussion
There are some data in rat models for self-sustaining status epilepticus (SSSE), with LCM reducing cumulative SSSE duration and neuronal hippocampal damage and preventing spontaneous recurrent seizures. 15 However, there are no large, adequately powered, randomized, actively controlled trials on the use of LCM in patients with SE. Nevertheless, some previously published retrospective series have observed efficacy rates of 70% or more when LCMs are used in SE patient treatment for both refractory and non-refractory SE.
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Although refractory SE is known to be more resistant to treatment, with a worse prognosis with each unsuccessful attempt to treat, 64.7% of RSE patients in this study demonstrated response to LCM treatment. In the context of superrefractory SE, which many of these cases were, intravenous LCM also seems to be fast, with most patients responding in the first 12 h after ivLCM administration. This response was achieved with a loading dose between 200 and 400 mg ivLCM. This is in line with the recently referred published data, but in contrast, in the present study LCM was always added as a third or later drug (benzodiazepines and at least one traditional AED) following the generally accepted guidelines. In previous studies only Kellinghaus et al. 11 and Hö fler et al. 13 performed a subgroup analysis concerning the time at which LCM was administered. No serious adverse side effects or drug-drug interactions were seen in these acutely ill patients. In summary, our study data suggest that ivLCM can be an effective add-on treatment, if standard drugs fail or are unsuitable. However, the scope of the results is limited due to the small sample size and lack of randomization. Nevertheless, this is the largest series after Kellinghaus et al., 11 with 39 patients with SE, and the first with prospective follow-up. The management of patients with SE is challenging and there is a paucity of data to guide treatment. We clearly need large, adequately powered, randomized, actively controlled trials to evaluate the efficacy of ivLCM and other AEDs. Expert opinion and guidelines may lend support to the treating physician, when drugs are used off label, but quite obviously this cannot replace randomized controlled studies.
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